AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market as a first-line treatment for breast cancer after camizestrant hit the mark in a ...
Stopping multiple myeloma treatment too soon could increase symptoms and shorten your life. Myeloma can “hide” as minimal residual disease (MRD), even when you feel well. Flow cytometry testing about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results